Vaccines Market Insight: Products, Pipelines & Market Outlook

Table of Contents

CHAPTER 1 INTRODUCTION

• 1.1 Vaccines
  • 1.1.1 General
  • 1.1.2 A brief history
• 1.2 The immune system
  • 1.2.1 Introduction
  • 1.2.2 MCH markers
  • 1.2.3 Lymphocytes
  • 1.2.4 B cells and T cells
  • 1.2.5 Cytokines and chemokines
  • 1.2.6 Phagocytes and granulocytes
  • 1.2.7 Complement proteins
  • 1.2.8 When the immune system fails
• 1.3 Immunological aspects of cancer
  • 1.3.1 Introduction
  • 1.3.2 The development of a tumour
  • 1.3.3 The treatment of cancer
• 1.4 Immunisation
• 1.5 Types of vaccine
  • 1.5.1 Prophylactic vaccines
  • 1.5.2 Therapeutic vaccines
  • 1.5.3 Recombinant vaccines
  • 1.5.4 DNA vaccines
  • 1.5.5 Autologous and allogenic vaccines
  • 1.5.6 Attenuated live vaccines
  • 1.5.7 Inactivated killed vaccines

CHAPTER 2 THE VACCINES MARKET

• 2.1 The vaccines market today
• 2.2 The potential for change
• 2.3 Market size
• 2.4 Major players
  • 2.4.1 GlaxoSmithKline (GSK)
    • 2.4.1.1 Company background
    • 2.4.1.2 Products
    • 2.4.1.3 Cervarix
    • 2.4.1.4 Other cancer candidates
    • 2.4.1.5 Other products in the pipeline
  • 2.4.2 Merck & Co
    • 2.4.2.1 Company background
    • 2.4.2.2 Gardasil
    • 2.4.2.3 Other launched products
    • 2.4.2.4 Products in the pipeline
  • 2.4.3 Novartis
    • 2.4.3.1 Company background
    • 2.4.3.2 Novartis' influenza vaccine pipeline
    • 2.4.3.3 Other products in the pipeline
  • 2.4.4 Sanofi-Aventis
    • 2.4.4.1 Company background
    • 2.4.4.2 Cancer vaccine products
    • 2.4.4.3 Other vaccine products
  • 2.4.5 Wyeth
    • 2.4.5.1 Company background
    • 2.4.5.2 Launched products
    • 2.4.5.3 Products in the pipeline
• 2.5 The importance of cancer vaccines in the overall market
• 2.6 Marketed cancer vaccines
  • 2.6.1 Cervarix - GlaxoSmithKline
  • 2.6.2 Gardasil - Merck & Co
  • 2.6.3 M-Vax - AVAX Technologies
  • 2.6.4 TheraCys - Sanofi Pasteur
  • 2.6.5 Bacillus Calmette-Guerin (BCG) vaccine - GSK
  • 2.6.6 Melacine - GSK
• 2.7 Other marketed vaccines
  • 2.7.1 Combination vaccinations
  • 2.7.2 Hepatitis B
  • 2.7.3 Hepatitis A
  • 2.7.4 Influenza
    • 2.7.4.1 FluMist - Aviron (now AstraZeneca)
    • 2.7.4.2 Fluviron/Flu-Immune - Powderject Pharmaceuticals (now Novartis)
    • 2.7.4.3 Fluviral - ID Biomedical (now GSK)
    • 2.7.4.4 Fluzone - Sanofi Pasteur
    • 2.7.4.5 Inflexal V and Nasalflu - Crucell
    • 2.7.4.6 LAIV - The Institute of Experimental Medicine, St Petersburg, Russia
    • 2.7.4.7 Other marketed influenza vaccines
  • 2.7.5 Haemophilus influenzae type B (HiB)
  • 2.7.6 Pertussis
  • 2.7.7 Rabies
  • 2.7.8 Typhoid
  • 2.7.9 Varicella and zoster
  • 2.7.10 Meningitis
    • 2.7.10.1 Meningitis (non-specific)
    • 2.7.10.2 Meningitis A
    • 2.7.10.3 Meningitis B
    • 2.7.10.4 Meningitis B/C
    • 2.7.10.5 Meningitis C
  • 2.7.11 Pneumococcus
  • 2.7.12 Poliomyelitis
  • 2.7.13 MMR and measles and rubella
  • 2.7.14 Smallpox
  • 2.7.15 Other indications
    • 2.7.15.1 Cholera
    • 2.7.15.2 Rotavirus
    • 2.7.15.3 Epidemic haemorrhagic fever
    • 2.7.15.4 Japanese encephalitis (JE)
    • 2.7.15.5 Lactobacillus
    • 2.7.15.6 Yellow fever
    • 2.7.15.7 Tick borne encephalitis (TBE)
    • 2.7.15.8 Q fever
    • 2.7.15.9 Ribosomal vaccine
    • 2.7.15.10 Urinary infection
  • 2.7.16 Launched therapeutic vaccines
    • 2.7.16.1 Leprovac
    • 2.7.16.2 Fluarix
    • 2.7.16.3 SolcoTrichovac
    • 2.7.16.4 PCEC
  • 2.7.17 Withdrawn vaccines

CHAPTER 3 CHALLENGES AND OPPORTUNITIES

• 3.1 Introduction
• 3.2 Unmet needs
  • 3.2.1 Cancer
  • 3.2.2 HIV/AIDS
  • 3.2.3 Autoimmune diseases
    • 3.2.3.1 Asthma
    • 3.2.3.2 Diabetes mellitus (type 1)
    • 3.2.3.3 Rheumatoid arthritis (RA)
  • 3.2.4 Infectious disease
    • 3.2.4.1 Tuberculosis (TB)
    • 3.2.4.2 Meningitis
  • 3.2.5 Malaria
  • 3.2.6 Bioterrorism threat
  • 3.2.7 Addiction
  • 3.2.8 Hepatitis C (HCV)
  • 3.2.9 CNS - Alzheimer' s disease
• 3.3 Technical challenges
  • 3.3.1 Alternatives to egg-grown vaccines
  • 3.3.2 Alternatives to needles
  • 3.3.3 Problems with supply and storage of vaccines
  • 3.3.4 Reducing the number of vaccinations
• 3.4 Commercial challenges
  • 3.4.1 Research and development
  • 3.4.2 Economies of scale
  • 3.4.3 Public opinion

CHAPTER 4 VACCINES IN DEVELOPMENT

• 4.1 Cancer
  • 4.1.1 Introduction
  • 4.1.2 Registered or awaiting approval
  • 4.1.3 Cancer vaccines in Phase III clinical development
    • 4.1.3.1 Brain cancer
    • 4.1.3.2 HPV
    • 4.1.3.3 Lung cancer and nsclc
    • 4.1.3.4 Lymphoma
    • 4.1.3.5 Pancreas cancer
    • 4.1.3.6 Prostate cancer
    • 4.1.3.7 Renal cancer
  • 4.1.4 Cancer vaccines in Phase II clinical development
    • 4.1.4.1 General
    • 4.1.4.2 Brain cancer
    • 4.1.4.3 Breast cancer
    • 4.1.4.4 Cervical cancer
    • 4.1.4.5 Colorectal cancer
    • 4.1.4.6 Leukaemia
    • 4.1.4.7 Lung cancer and nsclc
    • 4.1.4.8 Lymphoma
    • 4.1.4.9 Melanoma
    • 4.1.4.10 Myeloma
    • 4.1.4.11 Prostate cancer
    • 4.1.4.12 Renal cancer
  • 4.1.5 Cancer vaccines in Phase I clinical development
    • 4.1.5.1 Multiple or unspecified targets
    • 4.1.5.2 Bladder cancer
    • 4.1.5.3 Brain cancer
    • 4.1.5.4 Breast cancer
    • 4.1.5.5 Head and neck cancer
    • 4.1.5.6 Liver cancer
    • 4.1.5.7 Lung and nsclc cancer
    • 4.1.5.8 Oesophageal cancer
    • 4.1.5.9 Ovarian and pancreatic cancers
    • 4.1.5.10 Prostate cancer
  • 4.1.6 Cancer vaccines in preclinical development
    • 4.1.6.1 Non-specified cancers
    • 4.1.6.2 General cancer targets
    • 4.1.6.3 Bone cancer
    • 4.1.6.4 Breast cancer
    • 4.1.6.5 Colorectal and colon cancer
    • 4.1.6.6 Gastric cancer
    • 4.1.6.7 HPV
    • 4.1.6.8 Leukaemia
    • 4.1.6.9 Liver cancer
    • 4.1.6.10 Lung cancer and nsclc
    • 4.1.6.11 Melanoma
    • 4.1.6.12 Myeloma
    • 4.1.6.13 Ovarian cancer
    • 4.1.6.14 Pancreatic cancer
    • 4.1.6.15 Prostate cancer
    • 4.1.6.16 Renal cancer
• 4.2 Infectious diseases
  • 4.2.1 AIDS/HIV
    • 4.2.1.1 The Aaron Diamond AIDS Research Center
    • 4.2.1.2 Alphavax
    • 4.2.1.3 Avant Immunotherapeutics
    • 4.2.1.4 Bavarian Nordic
    • 4.2.1.5 Bionor Immuno
    • 4.2.1.6 Cytrx
    • 4.2.1.7 Dong-A
    • 4.2.1.8 EuroVac
    • 4.2.1.9 FIT Biotech
    • 4.2.1.10 Genecure
    • 4.2.1.11 Genetic Immunity
    • 4.2.1.12 Geovax
    • 4.2.1.13 GlaxoSmithKline
    • 4.2.1.14 Immunitor
    • 4.2.1.15 Merck & Co
    • 4.2.1.16 Neovacs
    • 4.2.1.17 Novartis
    • 4.2.1.18 Oxford Biomedica
    • 4.2.1.19 Pharmexa
    • 4.2.1.20 Powdermed
    • 4.2.1.21 Sanofi-Aventis
    • 4.2.1.22 St Jude' s Hospital, Memphis
    • 4.2.1.23 Targeted Genetics
    • 4.2.1.24 Therion Biologics
    • 4.2.1.25 The Vaccine Research Center (VRC)
    • 4.2.1.26 Vaxgen
    • 4.2.1.27 Vical
    • 4.2.1.28 Virax
    • 4.2.1.29 Virionics
    • 4.2.1.30 Wyeth
    • 4.2.1.31 Non-industry collaborations
  • 4.2.2 Hepatitis (excluding paediatric combination vaccines)
    • 4.2.2.1 Hepatitis B (HBV)
    • 4.2.2.2 Hepatitis C (HCV)
    • 4.2.2.3 Hepatitis E
    • 4.2.3 Influenza
    • 4.2.3.1 Acambis
    • 4.2.3.2 Alphavax
    • 4.2.3.3 Baxter
    • 4.2.3.4 Crucell
    • 4.2.3.5 CSL
    • 4.2.3.6 Dynport Vaccine Company
    • 4.2.3.7 Generex
    • 4.2.3.8 GlaxoSmithKline
    • 4.2.3.9 Iomai
    • 4.2.3.10 Medimmune
    • 4.2.3.11 Merck & Co
    • 4.2.3.12 Nasvax
    • 4.2.3.13 Novartis
    • 4.2.3.14 Novavax
    • 4.2.3.15 Powdermed
    • 4.2.3.16 Protein Sciences
    • 4.2.3.17 Sanofi-Aventis
    • 4.2.3.18 Sinovac Biotech
    • 4.2.3.19 Solvay
  • 4.2.4 Malaria
  • 4.2.5 Meningitis and pneumococcal infection
    • 4.2.5.1 China Biopharma
    • 4.2.5.2 Emergent Biosolutions
    • 4.2.5.3 GlaxoSmithKline
    • 4.2.5.4 LG Life Sciences
    • 4.2.5.5 Novartis
    • 4.2.5.6 Sanofi-Aventis
    • 4.2.5.7 Wyeth
  • 4.2.6 Tuberculosis
  • 4.2.7 Other infectious diseases
    • 4.2.7.1 Cholera
    • 4.2.7.2 Dengue fever
    • 4.2.7.3 Ebola and Marburg infections
    • 4.2.7.4 Helicobacter pylori
    • 4.2.7.5 Japanese encephalitis
    • 4.2.7.6 Rabies
    • 4.2.7.7 Rotavirus
    • 4.2.7.8 Typhoid fever
    • 4.2.7.9 West Nile virus infection
    • 4.2.7.10 Yellow fever
• 4.3 Other indications
  • 4.3.1 Addiction
  • 4.3.2 Allergy and asthma
  • 4.3.3 Autoimmune diseases
    • 4.3.3.1 Diabetes
    • 4.3.3.2 Rheumatoid arthritis (RA)
  • 4.3.4 Bioterrorist threats
    • 4.3.4.1 Anthrax
    • 4.3.4.2 Botulinum
    • 4.3.4.3 Plague
    • 4.3.4.4 Smallpox
  • 4.3.5 Alzheimer' s disease
  • 4.3.6 Obesity

CHAPTER 5 COMPANY PROFILES

• 5.1 Introduction
• 5.2 Æterna Zentaris
  • 5.2.1 Company overview
  • 5.2.2 Financial data
  • 5.2.3 Products
  • 5.2.4 R&D portfolio
• 5.3 Argos Therapeutics
  • 5.3.1 Company overview
  • 5.3.2 Financial data
  • 5.3.3 Products
  • 5.3.4 R&D portfolio
• 5.4 Avant Immunotherapeutics
  • 5.4.1 Company overview
  • 5.4.2 Financial data
  • 5.4.3 Products
  • 5.4.4 R&D portfolio
• 5.5 AVAX TECHNOLOGIES
  • 5.5.1 Company overview
  • 5.5.2 Financial data
  • 5.5.3 Products
  • 5.5.4 R&D portfolio
• 5.6 BT Pharma
  • 5.6.1 Company overview
  • 5.6.2 Financial data
  • 5.6.3 Products
  • 5.6.4 R&D portfolio
• 5.7 Bavarian Nordic
  • 5.7.1 Company overview
  • 5.7.2 Financial data
  • 5.7.3 R&D portfolio
• 5.8 Baxter International
  • 5.8.1 Company overview
  • 5.8.2 Financial data
  • 5.8.3 Products
  • 5.8.4 R&D portfolio
• 5.9 Cancer Research Technology
  • 5.9.1 Company overview
  • 5.9.2 Financial data
  • 5.9.3 Products
  • 5.9.4 R&D portfolio
• 5.10 Cell Genesys
  • 5.10.1 Company overview
  • 5.10.2 Financial data
  • 5.10.3 Products
  • 5.10.4 R&D portfolio
• 5.11 Cellgenix Technologie Transfer
  • 5.11.1 Company overview
  • 5.11.2 Financial data
  • 5.11.3 Products
  • 5.11.4 R&D portfolio
• 5.12 Celtic Pharma
  • 5.12.1 Company overview
  • 5.12.2 Financial data
  • 5.12.3 Products
  • 5.12.4 R&D portfolio
• 5.13 Crucell
  • 5.13.1 Company overview
  • 5.13.2 Financial data
  • 5.13.3 Products
  • 5.13.4 R&D portfolio
• 5.14 CSL
  • 5.14.1 Company overview
  • 5.14.2 Financial data
  • 5.14.3 Products
  • 5.14.4 R&D portfolio
• 5.15 Cytos Biotechnology
  • 5.15.1 Company overview
  • 5.15.2 Financial data
  • 5.15.3 Products
  • 5.15.4 R&D portfolio
• 5.16 Dendreon
  • 5.16.1 Company overview
  • 5.16.2 Financial data
  • 5.16.3 Products
  • 5.16.4 R&D portfolio
• 5.17 FIT Biotech
  • 5.17.1 Company overview
  • 5.17.2 Financial data
  • 5.17.3 Products
  • 5.17.4 R&D portfolio
• 5.18 Generex
  • 5.18.1 Company overview
  • 5.18.2 Financial data
  • 5.18.3 Products
  • 5.18.4 R&D portfolio
• 5.19 Geron
  • 5.19.1 Company overview
  • 5.19.2 Financial data
  • 5.19.3 Products
  • 5.19.4 R&D portfolio
• 5.20 Immunocellular Therapeutics
  • 5.20.1 Company overview
  • 5.20.2 Financial data
  • 5.20.3 Products
  • 5.20.4 R&D portfolio
• 5.21 Immunofrontier
  • 5.21.1 Company overview
  • 5.21.2 Financial data
  • 5.21.3 Products
  • 5.21.4 R&D portfolio
• 5.22 Immunomedics
  • 5.22.1 Company overview
  • 5.22.2 Financial data
  • 5.22.3 Products
  • 5.22.4 R&D portfolio
• 5.23 Immunotope
  • 5.23.1 Company overview
  • 5.23.2 Financial data
  • 5.23.3 Products
  • 5.23.4 R&D portfolio
• 5.24 Immvarx
  • 5.24.1 Company overview
  • 5.24.2 Financial data
  • 5.24.3 Products
  • 5.24.4 R&D portfolio
• 5.25 Juvaris Biotherapeutics
  • 5.25.1 Company overview
  • 5.25.2 Financial data
  • 5.25.3 Products
  • 5.25.4 R&D portfolio
• 5.26 Molmed
  • 5.26.1 Company overview
  • 5.26.2 Financial data
  • 5.26.3 Products
  • 5.26.4 R&D portfolio
• 5.27 Mologen
  • 5.27.1 Company overview
  • 5.27.2 Financial data
  • 5.27.3 Products
  • 5.27.4 R&D portfolio
• 5.28 Neovacs
  • 5.28.1 Company overview
  • 5.28.2 Financial data
  • 5.28.3 Products
  • 5.28.4 R&D portfolio
• 5.29 Newlink Genetics
  • 5.29.1 Company overview
  • 5.29.2 Financial data
  • 5.29.3 Products
  • 5.29.4 R&D portfolio
• 5.30 Oxford Biomedica
  • 5.30.1 Company overview
  • 5.30.2 Financial data
  • 5.30.3 Products
  • 5.30.4 R&D portfolio
• 5.31 Pepscan Systems
  • 5.31.1 Company overview
  • 5.31.2 Financial data
  • 5.31.3 Products
  • 5.31.4 R&D portfolio
• 5.32 Progenics Pharmaceuticals
  • 5.32.1 Company overview
  • 5.32.2 Financial data
  • 5.32.3 Products
  • 5.32.4 R&D portfolio
• 5.33 Targepeutics
  • 5.33.1 Company overview
  • 5.33.2 Financial data
  • 5.33.3 Products
  • 5.33.4 R&D portfolio
• 5.34 Therion Biologies
  • 5.34.1 Company overview
  • 5.34.2 Financial data
  • 5.34.3 Products
  • 5.34.4 R&D portfolio
• 5.35 Vaxon Biotech
  • 5.35.1 Company overview
  • 5.35.2 Financial data
  • 5.35.3 Products
  • 5.35.4 R&D portfolio
• 5.36 Virionics
  • 5.36.1 Company overview
  • 5.36.2 Financial data
  • 5.36.3 Products
  • 5.36.4 R&D portfolio

LIST OF TABLES

• Table 1.1 Global deaths by cancer type
• Table 1.2 Reduction in diseases in Europe between 1998 and 2004
• Table 2.1 Launched vaccines currently available by indication
• Table 5.1 Financial data for Æterna Zentaris
• Table 5.2 Financial data for Avant Immunotherapeutics 2003-2006 (US$ million)
• Table 5.3 Financial data for AVAX Technologies (US$ million)
• Table 5.4 Financial data for Bavarian Nordic 2003-2006 (DKr million)
• Table 5.5 Financial data for Baxter International 2003-2006 (US$ million)
• Table 5.6 Financial data for Cell Genesys 2002-2006 (US$ million)
• Table 5.7 Financial data for Crucell (€ million)
• Table 5.8 Financial data for CSL 2002-2006 (AUS$ million)
• Table 5.9 Financial data for Cytos Biotechnology 2002-2006 (SwFr million)
• Table 5.10 Financial data for Dendreon 2002-2006 (US$ million)
• Table 5.11 Financial data for Generex 2002-2006 (US$ million)
• Table 5.12 Financial data for Geron 2002-2006 (US$ million)
• Table 5.13 Financial data for ICT (US$ million)
• Table 5.14 Financial data for Immunomedics 2002-2006 (US$ million)
• Table 5.15 Financial data for Mologen (€ million)
• Table 5.16 Financial data for Oxford Biomedica 2002-2006 (£ million)
• Table 5.17 Financial data for Progenics Pharmaceuticals 2003-2006 (US$ million)

LIST OF FIGURES

• Figure 1.1 Trends in the vaccine industry
• Figure 1.2 Trends in the development of prophylactic vaccines
• Figure 1.3 Trends in the development of therapeutic vaccines
• Figure 1.4 Trends in the development of recombinant vaccines